Personalized mRNA therapy shows promise against melanoma in late-stage trial

Merck and Moderna announced that their personalized mRNA cancer treatment significantly reduced melanoma recurrence in a large late-stage trial, a first for such therapies. Experts have hailed the results as a breakthrough, though the drug is not yet approved. The success marks a major step in applying mRNA technology to cancer treatment.